NEW YORK (GenomeWeb) – Diagnostics firm OncoCyte said today that it has raised $5.74 million through the cash exercise of 1,766,923 common stock purchase warrants by certain warrant holders.

Oncocyte President and CEO William Annet said in a statement that the proceeds will help advance the development of the firm's novel liquid biopsy diagnostics for lung and breast cancer and prepare for the launch of its lung cancer diagnostic in the second half of 2017.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.